Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adding Mitomycin to Bacillus of Calmette-Guerin (BCG) as Adjuvant Intravesical Therapy for High-risk, Non-Muscle-invasive Bladder Cancer: a Randomised Phase 3 Trial

NCT02948543 is registered in ClinicalTrials.gov with University of Sydney as lead sponsor.

NCT NCT02948543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02948543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adding Mitomycin to Bacillus of Calmette-Guerin (BCG) as Adjuvant Intravesical Therapy for High-risk, Non-Muscle-invasive Bladder Cancer: a Randomised Phase 3 Trial
Lead sponsor
University of Sydney
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2013
Completion date
December 31, 2024
Enrollment
501 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer